Table 3.
Variable & range (days) | KI (0–2) | b (2 onwards) | KI(2–7) | KI (7–14) | KI (14–28) | b (2–28) | KI (2–28) |
Mean* (& no. of patients) | 0.513(87) | 0.123 (75) | 0.161 (68) | 0.094 (60) | 0.071 (43) | 0.077 (44) | 0.081 (44) |
Standard deviation* | 0.554 | 0.116 | 0.220 | 0.123 | 0.072 | 0.048 | 0.054 |
Mean* (& no. of patients): | |||||||
SHT | 0.540 (49) | 0.095 (44) | 0.121 (42) | 0.091 (38) | 0.053 (26) | 0.057 (27) | 0.060 (27) |
SHRZ | 0.479 (38) | 0.163 (31) | 0.225 (26) | 0.099 (22) | 0.099 (17) | 0.109 (17) | 0.115 (17) |
HIV- | 0.526 (59) | 0.099 (52) | 0.124 (48) | 0.086 (44) | 0.072 (34) | 0.076 (34) | 0.079 (34) |
HIV+ | 0.486 (28) | 0.177 (23) | 0.250 (20) | 0.114 (16) | 0.066 (9) | 0.080 (10) | 0.087 (10) |
2-way anova† | |||||||
Treatment F (& p) | 0.3 (0.6) | 8.8 (0.004) | 4.2 (0.044) | 0.0(1.0) | 2.7 (0.1) | 14.4(0.0005) | 9.9 (0.003) |
HIV status F (& p) | 0.01 (0.9) | 7.7 (0.007) | 4.1 (0.051) | 0.4 (0.5) | 0.1 (0.7) | 0.01 (0.9) | 0.20 (0.7) |
* Means and standard deviations of untransformed data. † Transformed data for KI (0–2), KI (2–7) and for all values of b except b(2–14). All interactions between treatment and HIV status were not significant. Statistically significant main effects (p < 0.05) are in bold type.